Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Gadget Island, Inc.
WARNING LETTER
•Gadget Island, Inc.•July 21, 2023

FDA WARNING_LETTER - Gadget Island, Inc. - July 21, 2023

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

The FDA issued a Warning Letter to Naeem Azizian regarding products sold on www.gearisle.com, www.smokewrap.com, and www.ultimamax.com. Between January and July 2023, the FDA reviewed www.gearisle.com, where "NUX Male Enhancement," "DYNAMITE Male Sexual Enhancement," and "ProPower Knight Plus 2550mg" were sold. Laboratory analyses confirmed these products contain undeclared tadalafil and sildenafil, active ingredients in FDA-approved prescription drugs Cialis and Viagra, respectively.

These products are unapproved new drugs, violating sections 505(a) and 301(d) of the FD&C Act (21 U.S.C. 355(a) and 331(d)). They are also misbranded drugs under section 502 and 301(a) of the FD&C Act (21 U.S.C. 352 and 331(a)) because their labeling fails to bear adequate directions for use, is false or misleading due to undeclared ingredients, and lacks adequate warnings. Tadalafil and sildenafil were not marketed as dietary supplements before their drug approval, excluding these products from the dietary supplement definition.

The undeclared PDE-5 inhibitors pose serious health risks, especially for individuals taking nitrates,

Company
Gadget Island, Inc.
Inspection Date
July 21, 2023
Product Type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Tina Smith (Director)
Open in Dashboard

ID · d4e942e3-f889-41be-a1d3-cc0caa3ce347

Violation Codes10
21 U.S.C. 331(a)21.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 35221 U.S.C. 321(ff)(3)(B)(i)21 U.S.C. 321(g)(1)21 U.S.C. 321(p)21 U.S.C. 352(f)(1)21 CFR 201.521 CFR 201.100(c)(2)

Full citation text and observation details available on the Dashboard.

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.